

PEDIATRIC MEDICINES: GLOBAL MARKETS



PHM170A
October 2014

Dr. Cheryl Lee Barton
Project Analyst

ISBN: 1-56965-971-0



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	2
METHODOLOGY AND INFORMATION SOURCES	3
ANALYSTS' CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
SUMMARY TABLE GLOBAL PEDIATRIC MARKET, THROUGH 2019 (\$ MILLIONS)	7
SUMMARY FIGURE GLOBAL PEDIATRIC MARKET, 2013-2019 (\$ MILLIONS)	7
CHAPTER 3 OVERVIEW	9
PEDIATRIC POPULATION	9
TABLE 1 GLOBAL PEDIATRIC MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	10
FIGURE 1 HISTORIC ANNUAL GROWTH RATES OF PEDIATRIC THERAPEUTIC SEGMENTS, 2004-2006 (%)	10
TABLE 2 DISTRIBUTION OF WORLD POPULATION IN THE 0-14-YEAR AND 15-24-YEAR AGE GROUPS BY REGION, 2013 AND 2050 (%)	11
TABLE 3 DISTRIBUTION OF WORLD POPULATION BY REGION IN THE 0-14-YEAR AGE GROUP, 2013-2100 (%)	12
TABLE 4 DISTRIBUTION OF WORLD POPULATION IN THE 0-14-YEAR AGE GROUP, 2013-2100 (MILLIONS)	12
OFF-LABEL DRUG USE	12
TABLE 5 OFF-LABEL CATEGORIES	13
TABLE 6 TYPES OF STUDIES REQUIRED WHEN MAKING A PIP SUBMISSION (NUMBER/%)	15
AREAS OF UNMET CLINICAL NEED	16
TABLE 7 KEY AREAS OF UNMET PEDIATRIC NEED CITED BY THE EMA 2013	17
MARKET RESISTORS AND DRIVERS	18
TABLE 8 DIFFERENCES BETWEEN ADULT AND PEDIATRIC TRIAL DESIGN	19
TABLE 9 AIMS OF THE PEDIATRIC FORMULATIONS INITIATIVE	20
ADDRESSABLE POPULATION	21
TABLE 10 PERCENTAGE OF POPULATION BETWEEN 0 AND 14 YEARS OF AGE BY REGION, 2013 (%)	22
GEOGRAPHIC AND THERAPEUTIC SEGMENTATION	23
TABLE 11 COMMON PEDIATRIC DISORDERS IN THE U.S. IN 2010 (MILLION/%)	24
CHAPTER 4 REGULATORY LANDSCAPE	27
THE UNITED STATES	27
TABLE 12 COMPARISON OF THE MAIN FEATURES OF THE U.S. PEDIATRIC INCENTIVE PROGRAMS	28
FIGURE 2 MAJOR MILESTONES OF PEDIATRIC LEGISLATION IN THE U.S. 1994 - 2012	29
THE EUROPEAN UNION	30

TOPIC	PAGE NO.
<i>FIGURE 3 GENERAL PRINCIPLES GUIDING PEDIATRIC DRUG DEVELOPMENT - THE ICH E-11 GUIDELINE</i>	30
<i>FIGURE 4 MAJOR MILESTONES OF PEDIATRIC LEGISLATION IN THE EU 1997 - 2007</i>	31
PEDIATRIC INVESTIGATION PLAN	32
<i>TABLE 13 CLASSIFICATION OF PEDIATRIC AGE CATEGORIES IN THE EU AND THE U.S.</i>	32
PEDIATRIC COMMITTEE	33
REWARDS AND INCENTIVES	33
<i>TABLE 14 PROCEDURAL GUIDELINES FOR PEDIATRIC DRUG DEVELOPMENT FOR EUROPE AND THE U.S.</i>	33
<i>TABLE 15 SCIENTIFIC GUIDELINES FOR PEDIATRIC DRUG DEVELOPMENT FOR EUROPE AND THE U.S.</i>	34
JAPAN	35
AUSTRALIA	36
CANADA	38
<i>TABLE 16 CURRENT LEGISLATIVE / REGULATORY PEDIATRIC INITIATIVES ACROSS KEY COUNTRIES GLOBALLY</i>	39
THE IMPACT OF NEW PEDIATRIC LEGISLATION	40
<i>TABLE 17 KEY GLOBAL PEDIATRIC INITIATIVES</i>	41
CHAPTER 5 BARRIERS TO ENTRY	44
ACCESS TO SAFE, AFFORDABLE AND EFFECTIVE MEDICINES	44
<i>TABLE 18 PRIORITY MEDICINES FOR CHILDREN UNDER FIVE YEARS OF AGE FOR MAJOR CAUSES OF MORTALITY, MORBIDITY, PALLIATIVE CARE AND CHILD SURVIVAL</i>	46
<i>TABLE 19 PRIORITY MEDICINES FOR CHILD HEALTH AND SURVIVAL IN NEED OF FURTHER RESEARCH AND DEVELOPMENT</i>	46
PEDIATRIC CLINICAL TRIALS	47
<i>FIGURE 5 PEDIATRIC AND ADULT TRIALS AS A PERCENTAGE, 2009-2013 (%)</i>	47
<i>TABLE 20 TOP 10 COUNTRIES RANKED BY STUDY PARTICIPATION AND PATIENT ENROLLMENT FOR STUDIES ON DRUGS 2007-2010 (NUMBER)</i>	48
<i>TABLE 21 TOP 10 COUNTRIES RANKED BY STUDY PARTICIPATION AND PATIENT ENROLLMENT FOR STUDIES ON VACCINES 2007-2010 (NUMBER)</i>	48
TRIAL DESIGNS	49
ETHICAL CONSIDERATIONS	49
RECRUITMENT AND RETENTION	50
AGE-APPROPRIATE FORMULATIONS	50
PRODUCT APPROVAL	51
UNITED STATES	51
EUROPEAN UNION	53
JAPAN	54
PRICING REIMBURSEMENT	55
UNITED STATES	55
EUROPEAN UNION	57
JAPAN	58
CHAPTER 6 ADVANCES IN PEDIATRIC MEDICINES	60
THERAPEUTIC AREAS FOR PEDIATRIC DRUG DEVELOPMENT	60
<i>FIGURE 6 THERAPEUTIC AREAS FOR PEDIATRIC DRUG APPROVALS SINCE THE IMPLEMENTATION OF PEDIATRIC REGULATIONS</i>	60

TOPIC	PAGE NO.
LEADING THERAPEUTIC TARGETS	61
ALLERGY AND RESPIRATORY CONDITIONS	61
FIGURE 7 APPROVED ALLERGY AND RESPIRATORY TREATMENTS	61
TABLE 22 PEDIATRIC DRUGS APPROVED FOR RESPIRATORY CONDITIONS THROUGH PEDIATRIC REGULATORY PATHWAYS, 2013 (\$ MILLIONS)	63
TABLE 23 GLOBAL SALES OF PEDIATRIC DRUGS APPROVED FOR RESPIRATORY CONDITIONS, 2013 (\$ MILLIONS/%)	64
TABLE 24 GLOBAL SALES OF PEDIATRIC DRUGS APPROVED FOR RESPIRATORY CONDITIONS BY REGION, 2013 (\$ MILLIONS)	64
TABLE 25 GLOBAL SALES OF TOP FIVE PEDIATRIC DRUGS APPROVED FOR RESPIRATORY CONDITIONS, 2013 (\$ MILLIONS/%)	65
ANTI-INFECTIVES	65
FIGURE 8 APPROVED PEDIATRIC ANTI-INFECTIVES	66
TABLE 26 PEDIATRIC DRUGS APPROVED FOR INFECTIOUS DISEASES THROUGH PEDIATRIC REGULATORY PATHWAYS, 2013 (\$ MILLIONS)	67
TABLE 27 GLOBAL SALES OF ANTI-INFECTIVE PEDIATRIC DRUGS, 2013 (\$ MILLIONS)	68
TABLE 28 GLOBAL SALES OF ANTI-INFECTIVE PEDIATRIC DRUGS APPROVED BY REGION, 2013 (\$ MILLIONS)	68
TABLE 29 GLOBAL SALES OF TOP FIVE PEDIATRIC DRUGS APPROVED FOR INFECTIOUS DISEASES, 2013 (\$ BILLIONS/%)	69
CENTRAL NERVOUS SYSTEM	69
FIGURE 9 APPROVED PEDIATRIC CNS MEDICATIONS	70
TABLE 30 PEDIATRIC DRUGS APPROVED FOR THE TREATMENT OF CNS CONDITIONS, 2013 (\$ MILLIONS)	70
TABLE 31 GLOBAL SALES OF PEDIATRIC DRUGS APPROVED FOR CNS CONDITIONS, 2013 (\$ MILLIONS)	72
TABLE 32 GLOBAL SALES OF PEDIATRIC DRUGS APPROVED FOR CNS CONDITIONS BY REGION, 2013 (\$ MILLIONS)	73
TABLE 33 GLOBAL SALES OF TOP FIVE PEDIATRIC DRUGS APPROVED FOR THE TREATMENT OF CNS CONDITIONS, 2013 (\$ MILLIONS/%)	73
PEDIATRIC VACCINES	73
FIGURE 10 APPROVED PEDIATRIC VACCINES	74
TABLE 34 LEADING PEDIATRIC AND ADOLESCENT VACCINES WORLDWIDE, 2013 (\$ MILLIONS)	75
TABLE 35 GLOBAL SALES OF VACCINES BY AGE/INDICATION, 2013 (\$ MILLIONS)	76
TABLE 36 GLOBAL SALES OF PEDIATRIC VACCINES BY REGION, 2013 (\$ MILLION)	76
TABLE 37 GLOBAL SALES OF TOP FIVE PEDIATRIC/ADOLESCENT VACCINES, 2013 (\$ MILLIONS/%)	76
ANTIDIABETIC THERAPIES	77
FIGURE 11 APPROVED PEDIATRIC ANTIDIABETIC THERAPIES	78
TABLE 38 LEADING PEDIATRIC ANTIDIABETIC THERAPIES, 2013 (\$ MILLIONS)	79
TABLE 39 GLOBAL SALES OF PEDIATRIC DRUGS APPROVED FOR THE TREATMENT OF DIABETES BY ROUTE, 2013 (\$ MILLIONS/%)	80
TABLE 40 GLOBAL SALES OF PEDIATRIC DRUGS APPROVED FOR THE TREATMENT OF DIABETES BY REGION, 2013 (\$ MILLIONS)	80
TABLE 41 GLOBAL SALES OF TOP FIVE PEDIATRIC ANTIDIABETIC DRUGS, 2013 (\$ MILLIONS/%)	80
ORPHAN DRUG DISEASES	81
TABLE 42 APPROVED PEDIATRIC ORPHAN DRUGS IN THE U.S., 2006-2009 (\$)	82
FIGURE 12 ORPHAN DRUG DESIGNATIONS RECEIVING FDA MARKETING APPROVAL, 2000-2009 (NUMBER)	83

TOPIC	PAGE NO.
<i>TABLE 43 PEDIATRIC (CATEGORY 1) DISEASES WITH MOST DESIGNATIONS (NUMBER)</i>	84
<i>FIGURE 13 ORPHAN PEDIATRIC PRODUCT APPROVALS, BY THERAPEUTIC CATEGORY (%)</i>	84
<i>FIGURE 14 ORPHAN PEDIATRIC PRODUCT APPROVALS BY DRUG TYPE, 2000-2009 (%)</i>	85
<i>TABLE 44 PEDIATRIC ORPHAN DRUGS IN CLINICAL DEVELOPMENT BY ORPHAN DISEASE, COMPANY, PRODUCT AND PHASE</i>	86
<i>TABLE 45 GLOBAL SALES OF PEDIATRIC DRUGS APPROVED IN ORPHAN CONDITIONS BY THERAPY AREA, 2013 (\$ MILLIONS)</i>	87
<i>TABLE 46 GLOBAL SALES OF PEDIATRIC DRUGS APPROVED IN ORPHAN CONDITIONS BY REGION, 2013 (\$ MILLIONS/%)</i>	88
<i>TABLE 47 GLOBAL SALES OF TOP FIVE PEDIATRIC DRUGS APPROVED IN ORPHAN CONDITIONS, 2013 (\$ MILLIONS)</i>	88
PEDIATRIC ONCOLOGY	88
<i>TABLE 48 GLOBAL APPROVED PEDIATRIC ONCOLOGY AGENTS IN EUROPE 2004-2014</i>	89
<i>TABLE 49 GLOBAL SALES OF PEDIATRIC DRUGS APPROVED IN ONCOLOGY CONDITIONS, BY REGION, 2013 (\$ MILLIONS)</i>	90
<i>TABLE 50 GLOBAL SALES OF TOP FIVE PEDIATRIC ONCOLOGY DRUGS, 2013 (\$ MILLIONS)</i>	91
OTHER PEDIATRIC THERAPIES	91
<i>TABLE 51 GLOBAL SALES OF PEDIATRIC DRUGS APPROVED FOR OTHER CONDITIONS, BY REGION, 2013 (\$ MILLIONS/%)</i>	91
<i>FIGURE 15 OTHER THERAPEUTIC AREAS OF PEDIATRIC PRODUCT APPROVAL</i>	91
CHAPTER 7 FUTURE OUTLOOK	94
MARKET TRENDS AND ANALYSIS	94
<i>TABLE 52 GLOBAL SALES OF PEDIATRIC DRUGS BY THERAPY AREA, THROUGH 2019 (\$ MILLIONS)</i>	94
REGIONAL TRENDS AND ANALYSIS	96
THE U.S.	96
<i>FIGURE 16 ESTIMATED U.S. PEDIATRIC PRODUCT SALES MARKET SHARES, 2019 (%)</i>	96
<i>TABLE 53 U.S. SALES OF PEDIATRIC DRUGS BY THERAPEUTIC AREA, THROUGH 2019 (\$ MILLIONS)</i>	97
EUROPE	97
<i>FIGURE 17 ESTIMATED EUROPEAN PEDIATRIC PRODUCT MARKET SHARE, 2019 (%)</i>	97
<i>TABLE 54 EUROPEAN SALES OF PEDIATRIC DRUGS BY THERAPEUTIC AREA, THROUGH 2019 (\$ MILLIONS)</i>	98
JAPAN	98
<i>FIGURE 18 ESTIMATED JAPANESE PEDIATRIC PRODUCT MARKET SHARE, 2019 (%)</i>	99
<i>TABLE 55 JAPANESE SALES OF PEDIATRIC DRUGS BY THERAPEUTIC AREA, THROUGH 2019 (\$ MILLIONS)</i>	100
REST OF WORLD (ROW)	100
<i>FIGURE 19 ESTIMATED REST OF WORLD PEDIATRIC PRODUCT MARKET SHARES, 2019 (%)</i>	101
<i>TABLE 56 REST OF WORLD SALES OF PEDIATRIC DRUGS BY THERAPEUTIC AREA, THROUGH 2019 (\$ MILLIONS)</i>	101
OVERALL CONCLUSIONS	102
CHAPTER 8 COMPANY PROFILES	104

TOPIC	PAGE NO.
LEADING PEDIATRIC COMPANIES	104
PIERRE FABRE DERMATOLOGIE	104
SWEDISH ORPHAN BIOVITRUM (SOBI)	104
VIROPHARMA	105
LEADING CLINICAL RESEARCH ORGANIZATIONS	106
AGILITY CLINICAL, INC.	106
CLINIGENE INTERNATIONAL LIMITED	106
CONET (CLINICAL OPERATIONS NETWORK)	107
COVANCE INC.	107
INC RESEARCH	108
PAREXEL INTERNATIONAL CORP.	108
PPD	109
PREMIER RESEARCH	109
PSI CRO AG	110
QUINTILES	110
WWCT GLOBAL	111
LEADING PEDIATRIC NETWORKS	112
INTERNATIONAL NETWORKS	112
European Network of Paediatric Research (Enpr-EMA)	112
Global Research in Pediatrics (GRiP)	112
Programme for Global Paediatric Research (PGPR)	112
NATIONAL NETWORKS	113
Medicines for Clinical Research Network (MCRN) - United Kingdom	113
Medicines for Clinical Research Network (MCRN) - Netherlands	113
Finnish Investigators Network for Paediatric Medicines (FINPEDMED) - Finland	114
Pediatric Trials Network (PTN) - United States	114
CHAPTER 9 REFERENCES	116
CHAPTER 10 ACRONYMS	127

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL PEDIATRIC MARKET, THROUGH 2019 (\$ MILLIONS)	7
TABLE 1 GLOBAL PEDIATRIC MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	10
TABLE 2 DISTRIBUTION OF WORLD POPULATION IN THE 0-14-YEAR AND 15-24-YEAR AGE GROUPS BY REGION, 2013 AND 2050 (%)	11
TABLE 3 DISTRIBUTION OF WORLD POPULATION BY REGION IN THE 0-14-YEAR AGE GROUP, 2013-2100 (%)	12
TABLE 4 DISTRIBUTION OF WORLD POPULATION IN THE 0-14-YEAR AGE GROUP, 2013-2100 (MILLIONS)	12
TABLE 5 OFF-LABEL CATEGORIES	13
TABLE 6 TYPES OF STUDIES REQUIRED WHEN MAKING A PIP SUBMISSION (NUMBER/%)	15
TABLE 7 KEY AREAS OF UNMET PEDIATRIC NEED CITED BY THE EMA 2013	17
TABLE 8 DIFFERENCES BETWEEN ADULT AND PEDIATRIC TRIAL DESIGN	19
TABLE 9 AIMS OF THE PEDIATRIC FORMULATIONS INITIATIVE	20
TABLE 10 PERCENTAGE OF POPULATION BETWEEN 0 AND 14 YEARS OF AGE BY REGION, 2013 (%)	22
TABLE 11 COMMON PEDIATRIC DISORDERS IN THE U.S. IN 2010 (MILLION/%)	24
TABLE 12 COMPARISON OF THE MAIN FEATURES OF THE U.S. PEDIATRIC INCENTIVE PROGRAMS	28
TABLE 13 CLASSIFICATION OF PEDIATRIC AGE CATEGORIES IN THE EU AND THE U.S.	32
TABLE 14 PROCEDURAL GUIDELINES FOR PEDIATRIC DRUG DEVELOPMENT FOR EUROPE AND THE U.S.	33
TABLE 15 SCIENTIFIC GUIDELINES FOR PEDIATRIC DRUG DEVELOPMENT FOR EUROPE AND THE U.S.	34
TABLE 16 CURRENT LEGISLATIVE / REGULATORY PEDIATRIC INITIATIVES ACROSS KEY COUNTRIES GLOBALLY	39
TABLE 17 KEY GLOBAL PEDIATRIC INITIATIVES	41
TABLE 18 PRIORITY MEDICINES FOR CHILDREN UNDER FIVE YEARS OF AGE FOR MAJOR CAUSES OF MORTALITY, MORBIDITY, PALLIATIVE CARE AND CHILD SURVIVAL	46
TABLE 19 PRIORITY MEDICINES FOR CHILD HEALTH AND SURVIVAL IN NEED OF FURTHER RESEARCH AND DEVELOPMENT	46
TABLE 20 TOP 10 COUNTRIES RANKED BY STUDY PARTICIPATION AND PATIENT ENROLLMENT FOR STUDIES ON DRUGS 2007-2010 (NUMBER)	48
TABLE 21 TOP 10 COUNTRIES RANKED BY STUDY PARTICIPATION AND PATIENT ENROLLMENT FOR STUDIES ON VACCINES 2007-2010 (NUMBER)	48
TABLE 22 PEDIATRIC DRUGS APPROVED FOR RESPIRATORY CONDITIONS THROUGH PEDIATRIC REGULATORY PATHWAYS, 2013 (\$ MILLIONS)	63
TABLE 23 GLOBAL SALES OF PEDIATRIC DRUGS APPROVED FOR RESPIRATORY CONDITIONS, 2013 (\$ MILLIONS/%)	64
TABLE 24 GLOBAL SALES OF PEDIATRIC DRUGS APPROVED FOR RESPIRATORY CONDITIONS BY REGION, 2013 (\$ MILLIONS)	64
TABLE 25 GLOBAL SALES OF TOP FIVE PEDIATRIC DRUGS APPROVED FOR RESPIRATORY CONDITIONS, 2013 (\$ MILLIONS/%)	65
TABLE 26 PEDIATRIC DRUGS APPROVED FOR INFECTIOUS DISEASES THROUGH PEDIATRIC REGULATORY PATHWAYS, 2013 (\$ MILLIONS)	67
TABLE 27 GLOBAL SALES OF ANTI-INFECTIVE PEDIATRIC DRUGS, 2013 (\$ MILLIONS)	68
TABLE 28 GLOBAL SALES OF ANTI-INFECTIVE PEDIATRIC DRUGS APPROVED BY REGION, 2013 (\$ MILLIONS)	68
TABLE 29 GLOBAL SALES OF TOP FIVE PEDIATRIC DRUGS APPROVED FOR INFECTIOUS DISEASES, 2013 (\$ BILLIONS/%)	69

TABLE HEADING	PAGE NO.
TABLE 30 PEDIATRIC DRUGS APPROVED FOR THE TREATMENT OF CNS CONDITIONS, 2013 (\$ MILLIONS)	70
TABLE 31 GLOBAL SALES OF PEDIATRIC DRUGS APPROVED FOR CNS CONDITIONS, 2013 (\$ MILLIONS)	72
TABLE 32 GLOBAL SALES OF PEDIATRIC DRUGS APPROVED FOR CNS CONDITIONS BY REGION, 2013 (\$ MILLIONS)	73
TABLE 33 GLOBAL SALES OF TOP FIVE PEDIATRIC DRUGS APPROVED FOR THE TREATMENT OF CNS CONDITIONS, 2013 (\$ MILLIONS/%)	73
TABLE 34 LEADING PEDIATRIC AND ADOLESCENT VACCINES WORLDWIDE, 2013 (\$ MILLIONS)	75
TABLE 35 GLOBAL SALES OF VACCINES BY AGE/INDICATION, 2013 (\$ MILLIONS)	76
TABLE 36 GLOBAL SALES OF PEDIATRIC VACCINES BY REGION, 2013 (\$ MILLION)	76
TABLE 37 GLOBAL SALES OF TOP FIVE PEDIATRIC/ADOLESCENT VACCINES, 2013 (\$ MILLIONS/%)	76
TABLE 38 LEADING PEDIATRIC ANTIDIABETIC THERAPIES, 2013 (\$ MILLIONS)	79
TABLE 39 GLOBAL SALES OF PEDIATRIC DRUGS APPROVED FOR THE TREATMENT OF DIABETES BY ROUTE, 2013 (\$ MILLIONS/%)	80
TABLE 40 GLOBAL SALES OF PEDIATRIC DRUGS APPROVED FOR THE TREATMENT OF DIABETES BY REGION, 2013 (\$ MILLIONS)	80
TABLE 41 GLOBAL SALES OF TOP FIVE PEDIATRIC ANTIDIABETIC DRUGS, 2013 (\$ MILLIONS/%)	80
TABLE 42 APPROVED PEDIATRIC ORPHAN DRUGS IN THE U.S., 2006-2009 (\$)	82
TABLE 43 PEDIATRIC (CATEGORY 1) DISEASES WITH MOST DESIGNATIONS (NUMBER)	84
TABLE 44 PEDIATRIC ORPHAN DRUGS IN CLINICAL DEVELOPMENT BY ORPHAN DISEASE, COMPANY, PRODUCT AND PHASE	86
TABLE 45 GLOBAL SALES OF PEDIATRIC DRUGS APPROVED IN ORPHAN CONDITIONS BY THERAPY AREA, 2013 (\$ MILLIONS)	87
TABLE 46 GLOBAL SALES OF PEDIATRIC DRUGS APPROVED IN ORPHAN CONDITIONS BY REGION, 2013 (\$ MILLIONS/%)	88
TABLE 47 GLOBAL SALES OF TOP FIVE PEDIATRIC DRUGS APPROVED IN ORPHAN CONDITIONS, 2013 (\$ MILLIONS)	88
TABLE 48 GLOBAL APPROVED PEDIATRIC ONCOLOGY AGENTS IN EUROPE 2004-2014	89
TABLE 49 GLOBAL SALES OF PEDIATRIC DRUGS APPROVED IN ONCOLOGY CONDITIONS, BY REGION, 2013 (\$ MILLIONS)	90
TABLE 50 GLOBAL SALES OF TOP FIVE PEDIATRIC ONCOLOGY DRUGS, 2013 (\$ MILLIONS)	91
TABLE 51 GLOBAL SALES OF PEDIATRIC DRUGS APPROVED FOR OTHER CONDITIONS, BY REGION, 2013 (\$ MILLIONS/%)	91
TABLE 52 GLOBAL SALES OF PEDIATRIC DRUGS BY THERAPY AREA, THROUGH 2019 (\$ MILLIONS)	94
TABLE 53 U.S. SALES OF PEDIATRIC DRUGS BY THERAPEUTIC AREA, THROUGH 2019 (\$ MILLIONS)	97
TABLE 54 EUROPEAN SALES OF PEDIATRIC DRUGS BY THERAPEUTIC AREA, THROUGH 2019 (\$ MILLIONS)	98
TABLE 55 JAPANESE SALES OF PEDIATRIC DRUGS BY THERAPEUTIC AREA, THROUGH 2019 (\$ MILLIONS)	100
TABLE 56 REST OF WORLD SALES OF PEDIATRIC DRUGS BY THERAPEUTIC AREA, THROUGH 2019 (\$ MILLIONS)	101

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL PEDIATRIC MARKET, 2013-2019 (\$ MILLIONS)	7
FIGURE 1 HISTORIC ANNUAL GROWTH RATES OF PEDIATRIC THERAPEUTIC SEGMENTS, 2004-2006 (%)	10
FIGURE 2 MAJOR MILESTONES OF PEDIATRIC LEGISLATION IN THE U.S. 1994 - 2012	29
FIGURE 3 GENERAL PRINCIPLES GUIDING PEDIATRIC DRUG DEVELOPMENT - THE ICH E-11 GUIDELINE	30
FIGURE 4 MAJOR MILESTONES OF PEDIATRIC LEGISLATION IN THE EU 1997 - 2007	31
FIGURE 5 PEDIATRIC AND ADULT TRIALS AS A PERCENTAGE, 2009-2013 (%)	47
FIGURE 6 THERAPEUTIC AREAS FOR PEDIATRIC DRUG APPROVALS SINCE THE IMPLEMENTATION OF PEDIATRIC REGULATIONS	60
FIGURE 7 APPROVED ALLERGY AND RESPIRATORY TREATMENTS	61
FIGURE 8 APPROVED PEDIATRIC ANTI-INFECTIVES	66
FIGURE 9 APPROVED PEDIATRIC CNS MEDICATIONS	70
FIGURE 10 APPROVED PEDIATRIC VACCINES	74
FIGURE 11 APPROVED PEDIATRIC ANTIDIABETIC THERAPIES	78
FIGURE 12 ORPHAN DRUG DESIGNATIONS RECEIVING FDA MARKETING APPROVAL, 2000-2009 (NUMBER)	83
FIGURE 13 ORPHAN PEDIATRIC PRODUCT APPROVALS, BY THERAPEUTIC CATEGORY (%)	84
FIGURE 14 ORPHAN PEDIATRIC PRODUCT APPROVALS BY DRUG TYPE, 2000-2009 (%)	85
FIGURE 15 OTHER THERAPEUTIC AREAS OF PEDIATRIC PRODUCT APPROVAL	91
FIGURE 16 ESTIMATED U.S. PEDIATRIC PRODUCT SALES MARKET SHARES, 2019 (%)	96
FIGURE 17 ESTIMATED EUROPEAN PEDIATRIC PRODUCT MARKET SHARE, 2019 (%)	97
FIGURE 18 ESTIMATED JAPANESE PEDIATRIC PRODUCT MARKET SHARE, 2019 (%)	99
FIGURE 19 ESTIMATED REST OF WORLD PEDIATRIC PRODUCT MARKET SHARES, 2019 (%)	101